APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Platinum Anti-tumor Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Platinum Anti-tumor Drugs Market Outlook and Growth Opportunities 2026

2 January 2026190 pages

Choose your research edition.

Industry ResearchPlatinum Anti-tumor Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Platinum Anti-tumor Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Platinum Anti-tumor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platinum Anti-tumor Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Platinum Anti-tumor Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Platinum Anti-tumor Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Platinum Anti-tumor Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Platinum Anti-tumor Drugs market include Teva, Sun Pharma, Sanofi, Novartis, Pfizer, Hengrui Medicine, Yi Bai Pharmaceutical, Viatris and SK Chemicals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Platinum Anti-tumor Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Platinum Anti-tumor Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Platinum Anti-tumor Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Platinum Anti-tumor Drugs market.

Platinum Anti-tumor Drugs Segment by Company

Teva

Sun Pharma

Sanofi

Novartis

Pfizer

Hengrui Medicine

Yi Bai Pharmaceutical

Viatris

SK Chemicals

Qilu Pharmaceutical

Dr Reddy's Laboratories

Debiopharm

ASK Pharma

Accord Healthcare

Platinum Anti-tumor Drugs Segment by Type

Oxaliplatin

Carboplatin

Cisplatin

Other

Platinum Anti-tumor Drugs Segment by Application

Ovarian Cancer

Lung Cancer

Colorectal Cancer

Other

Platinum Anti-tumor Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Platinum Anti-tumor Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Platinum Anti-tumor Drugs key companies, revenue, market share, and recent developments.

3. To split the Platinum Anti-tumor Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Platinum Anti-tumor Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Platinum Anti-tumor Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Platinum Anti-tumor Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum Anti-tumor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platinum Anti-tumor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum Anti-tumor Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Platinum Anti-tumor Drugs industry.

Chapter 3: Detailed analysis of Platinum Anti-tumor Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Platinum Anti-tumor Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Platinum Anti-tumor Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Platinum Anti-tumor Drugs Industry Trends Table 2. Platinum Anti-tumor Drugs Industry Drivers Table 3. Platinum Anti-tumor Drugs Industry Opportunities and Challenges Table 4. Platinum Anti-tumor Drugs Industry Restraints Table 5. Global Platinum Anti-tumor Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Platinum Anti-tumor Drugs Revenue Share by Company (2021-2026) Table 7. Global Platinum Anti-tumor Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Platinum Anti-tumor Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Platinum Anti-tumor Drugs Company, Product Type & Application Table 10. Global Platinum Anti-tumor Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Platinum Anti-tumor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oxaliplatin Table 15. Significant Companies of Carboplatin Table 16. Significant Companies of Cisplatin Table 17. Significant Companies of Other Table 18. Global Platinum Anti-tumor Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Platinum Anti-tumor Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Platinum Anti-tumor Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Platinum Anti-tumor Drugs Sales Value Share by Type (2021-2026) Table 22. Global Platinum Anti-tumor Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Ovarian Cancer Table 24. Significant Companies of Lung Cancer Table 25. Significant Companies of Colorectal Cancer Table 26. Significant Companies of Other Table 27. Global Platinum Anti-tumor Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Platinum Anti-tumor Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Platinum Anti-tumor Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Platinum Anti-tumor Drugs Sales Value Share by Application (2021-2026) Table 31. Global Platinum Anti-tumor Drugs Sales Value Share by Application (2027-2032) Table 32. Global Platinum Anti-tumor Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Platinum Anti-tumor Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Platinum Anti-tumor Drugs Sales Value Share by Region (2021-2026) Table 35. Global Platinum Anti-tumor Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Platinum Anti-tumor Drugs Sales Value Share by Region (2027-2032) Table 37. Global Platinum Anti-tumor Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Platinum Anti-tumor Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Platinum Anti-tumor Drugs Sales Value Market Share by Country (2021-2026) Table 40. Global Platinum Anti-tumor Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Platinum Anti-tumor Drugs Sales Value Market Share by Country (2027-2032) Table 42. Teva Company Information Table 43. Teva Business Overview Table 44. Teva Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Teva Platinum Anti-tumor Drugs Product Portfolio Table 46. Teva Recent Development Table 47. Sun Pharma Company Information Table 48. Sun Pharma Business Overview Table 49. Sun Pharma Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Sun Pharma Platinum Anti-tumor Drugs Product Portfolio Table 51. Sun Pharma Recent Development Table 52. Sanofi Company Information Table 53. Sanofi Business Overview Table 54. Sanofi Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Sanofi Platinum Anti-tumor Drugs Product Portfolio Table 56. Sanofi Recent Development Table 57. Novartis Company Information Table 58. Novartis Business Overview Table 59. Novartis Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Novartis Platinum Anti-tumor Drugs Product Portfolio Table 61. Novartis Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Pfizer Platinum Anti-tumor Drugs Product Portfolio Table 66. Pfizer Recent Development Table 67. Hengrui Medicine Company Information Table 68. Hengrui Medicine Business Overview Table 69. Hengrui Medicine Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio Table 71. Hengrui Medicine Recent Development Table 72. Yi Bai Pharmaceutical Company Information Table 73. Yi Bai Pharmaceutical Business Overview Table 74. Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio Table 76. Yi Bai Pharmaceutical Recent Development Table 77. Viatris Company Information Table 78. Viatris Business Overview Table 79. Viatris Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Viatris Platinum Anti-tumor Drugs Product Portfolio Table 81. Viatris Recent Development Table 82. SK Chemicals Company Information Table 83. SK Chemicals Business Overview Table 84. SK Chemicals Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. SK Chemicals Platinum Anti-tumor Drugs Product Portfolio Table 86. SK Chemicals Recent Development Table 87. Qilu Pharmaceutical Company Information Table 88. Qilu Pharmaceutical Business Overview Table 89. Qilu Pharmaceutical Platinum Anti-tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio Table 91. Qilu Pharmaceutical Recent Development Table 92. Dr Reddy's Laboratories Company Information Table 93. Dr Reddy's Laboratories Business Overview Table 94. Dr Reddy's Laboratories Platinum Anti-tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio Table 96. Dr Reddy's Laboratories Recent Development Table 97. Debiopharm Company Information Table 98. Debiopharm Business Overview Table 99. Debiopharm Platinum Anti-tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Debiopharm Platinum Anti-tumor Drugs Product Portfolio Table 101. Debiopharm Recent Development Table 102. ASK Pharma Company Information Table 103. ASK Pharma Business Overview Table 104. ASK Pharma Platinum Anti-tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. ASK Pharma Platinum Anti-tumor Drugs Product Portfolio Table 106. ASK Pharma Recent Development Table 107. Accord Healthcare Company Information Table 108. Accord Healthcare Business Overview Table 109. Accord Healthcare Platinum Anti-tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio Table 111. Accord Healthcare Recent Development Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Platinum Anti-tumor Drugs Product Image Figure 2. Global Platinum Anti-tumor Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platinum Anti-tumor Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Platinum Anti-tumor Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oxaliplatin Image Figure 8. Carboplatin Image Figure 9. Cisplatin Image Figure 10. Other Image Figure 11. Global Platinum Anti-tumor Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Platinum Anti-tumor Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Platinum Anti-tumor Drugs Sales Value Share by Type (2021-2032) Figure 14. Ovarian Cancer Image Figure 15. Lung Cancer Image Figure 16. Colorectal Cancer Image Figure 17. Other Image Figure 18. Global Platinum Anti-tumor Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Platinum Anti-tumor Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Platinum Anti-tumor Drugs Sales Value Share by Application (2021-2032) Figure 21. Global Platinum Anti-tumor Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Platinum Anti-tumor Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Platinum Anti-tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. North America Platinum Anti-tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Platinum Anti-tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Platinum Anti-tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Platinum Anti-tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Platinum Anti-tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Platinum Anti-tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. South America Platinum Anti-tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Platinum Anti-tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Platinum Anti-tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Oxaliplatin
  • Carboplatin
  • Cisplatin
  • Other
Applications
  • Ovarian Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other
Companies covered
  • Teva
  • Sun Pharma
  • Sanofi
  • Novartis
  • Pfizer
  • Hengrui Medicine
  • Yi Bai Pharmaceutical
  • Viatris
  • SK Chemicals
  • Qilu Pharmaceutical
  • Dr Reddy's Laboratories
  • Debiopharm
  • ASK Pharma
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Platinum Anti-tumor Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Platinum Anti-tumor Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Platinum Anti-tumor Drugs Market Dynamics
  1. 2.1 Platinum Anti-tumor Drugs Industry Trends
  2. 2.2 Platinum Anti-tumor Drugs Industry Drivers
  3. 2.3 Platinum Anti-tumor Drugs Industry Opportunities and Challenges
  4. 2.4 Platinum Anti-tumor Drugs Industry Restraints
3 Platinum Anti-tumor Drugs Market by Company
  1. 3.1 Global Platinum Anti-tumor Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Platinum Anti-tumor Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Platinum Anti-tumor Drugs Company Ranking (2024-2026)
  4. 3.4 Global Platinum Anti-tumor Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Platinum Anti-tumor Drugs Company Product Type and Application
  6. 3.6 Global Platinum Anti-tumor Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Platinum Anti-tumor Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Platinum Anti-tumor Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Platinum Anti-tumor Drugs Market by Type
  1. 4.1 Platinum Anti-tumor Drugs Type Introduction
  2. 4.1.1 Oxaliplatin
  3. 4.1.2 Carboplatin
  4. 4.1.3 Cisplatin
  5. 4.1.4 Other
  6. 4.2 Global Platinum Anti-tumor Drugs Sales Value by Type
  7. 4.2.1 Global Platinum Anti-tumor Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Platinum Anti-tumor Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Platinum Anti-tumor Drugs Sales Value Share by Type (2021-2032)
5 Platinum Anti-tumor Drugs Market by Application
  1. 5.1 Platinum Anti-tumor Drugs Application Introduction
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Lung Cancer
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Other
  6. 5.2 Global Platinum Anti-tumor Drugs Sales Value by Application
  7. 5.2.1 Global Platinum Anti-tumor Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Platinum Anti-tumor Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Platinum Anti-tumor Drugs Sales Value Share by Application (2021-2032)
6 Platinum Anti-tumor Drugs Regional Value Analysis
  1. 6.1 Global Platinum Anti-tumor Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Platinum Anti-tumor Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Platinum Anti-tumor Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Platinum Anti-tumor Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Platinum Anti-tumor Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Platinum Anti-tumor Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Platinum Anti-tumor Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Platinum Anti-tumor Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Platinum Anti-tumor Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Platinum Anti-tumor Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Platinum Anti-tumor Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Platinum Anti-tumor Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Platinum Anti-tumor Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Platinum Anti-tumor Drugs Sales Value Share by Country, 2025 VS 2032
7 Platinum Anti-tumor Drugs Country-level Value Analysis
  1. 7.1 Global Platinum Anti-tumor Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Platinum Anti-tumor Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Platinum Anti-tumor Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Platinum Anti-tumor Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Platinum Anti-tumor Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Platinum Anti-tumor Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Platinum Anti-tumor Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Platinum Anti-tumor Drugs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sun Pharma
  8. 8.2.1 Sun Pharma Company Information
  9. 8.2.2 Sun Pharma Business Overview
  10. 8.2.3 Sun Pharma Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharma Platinum Anti-tumor Drugs Product Portfolio
  12. 8.2.5 Sun Pharma Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Platinum Anti-tumor Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Platinum Anti-tumor Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Platinum Anti-tumor Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Hengrui Medicine
  32. 8.6.1 Hengrui Medicine Company Information
  33. 8.6.2 Hengrui Medicine Business Overview
  34. 8.6.3 Hengrui Medicine Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio
  36. 8.6.5 Hengrui Medicine Recent Developments
  37. 8.7 Yi Bai Pharmaceutical
  38. 8.7.1 Yi Bai Pharmaceutical Company Information
  39. 8.7.2 Yi Bai Pharmaceutical Business Overview
  40. 8.7.3 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
  42. 8.7.5 Yi Bai Pharmaceutical Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Platinum Anti-tumor Drugs Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 SK Chemicals
  50. 8.9.1 SK Chemicals Company Information
  51. 8.9.2 SK Chemicals Business Overview
  52. 8.9.3 SK Chemicals Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 SK Chemicals Platinum Anti-tumor Drugs Product Portfolio
  54. 8.9.5 SK Chemicals Recent Developments
  55. 8.10 Qilu Pharmaceutical
  56. 8.10.1 Qilu Pharmaceutical Company Information
  57. 8.10.2 Qilu Pharmaceutical Business Overview
  58. 8.10.3 Qilu Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
  60. 8.10.5 Qilu Pharmaceutical Recent Developments
  61. 8.11 Dr Reddy's Laboratories
  62. 8.11.1 Dr Reddy's Laboratories Company Information
  63. 8.11.2 Dr Reddy's Laboratories Business Overview
  64. 8.11.3 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio
  66. 8.11.5 Dr Reddy's Laboratories Recent Developments
  67. 8.12 Debiopharm
  68. 8.12.1 Debiopharm Company Information
  69. 8.12.2 Debiopharm Business Overview
  70. 8.12.3 Debiopharm Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Debiopharm Platinum Anti-tumor Drugs Product Portfolio
  72. 8.12.5 Debiopharm Recent Developments
  73. 8.13 ASK Pharma
  74. 8.13.1 ASK Pharma Company Information
  75. 8.13.2 ASK Pharma Business Overview
  76. 8.13.3 ASK Pharma Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 ASK Pharma Platinum Anti-tumor Drugs Product Portfolio
  78. 8.13.5 ASK Pharma Recent Developments
  79. 8.14 Accord Healthcare
  80. 8.14.1 Accord Healthcare Company Information
  81. 8.14.2 Accord Healthcare Business Overview
  82. 8.14.3 Accord Healthcare Platinum Anti-tumor Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio
  84. 8.14.5 Accord Healthcare Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst